Table 3.
Clinical follow-up and treatment
| Case | Cr at last follow-up (mg/dl) | Proteinuria at last follow-up (g/gCr) | Treatment | Observation period (months) |
|---|---|---|---|---|
| 1 | 1.28 | 4.29 | PSL, ARB, CNI, ATV | 34.0 |
| 2 | 0.76 | 0.16 | PSL, ARB | 32.1 |
| 3 | 0.94 | 0.07 | PSL | 58.4 |
| 5 | 0.97 | 0.07 | NA | NA |
| 8 | 1.03 | 1.40 | PSL, ARB | 3.1 |
| 9 | 0.79 | 0.37 | PSL, ARB, ATV | 37.0 |
| 10 | 0.63 | 0.11 | PSL, ARB | 62.6 |
| 11 | 0.71 | 0.03 | NA | NA |
| 13 | 0.92 | 0.03 | PSL | 49.9 |
| 14 | 0.56 | 11.86 | no treatment | 43.0 |
| Average | 0.86 | 1.84 | – | 40.0 |
ARB angiotensin II receptor blocker, ATV atorvastatin, CNI calcineurin inhibitor, Cr creatinine, NA not available, PSL prednisone